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The use of a single-pass albumin dialysis (SPAD) to correct 
severe hyperbilirubinemia in Weil's disease: a case report
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Liver failure, regardless of the cause, carries a high risk of morbidity and mor-
tality. Many of the toxins that accumulate in liver failure are poorly water-solu-
ble and are thus transported through the bloodstream bound to albumins. Renal
replacement therapy does not significantly alter the concentration of bilirubin
and other albumin-bound toxins in the serum.  In patients with liver failure addi-
tional detoxification methods are needed. There are several artificial extracor-
poreal liver support systems based on the principle of albumin but their avail-
ability is limited due to high cost and requirement of operators with special
training.  There have been several reports of using SPAD (single pass albumin
dialysis) as an effective alternative. The main advantage of this method is that it
can be performed using conventional renal replacement therapy (RRT) devices.
In this report, the authors report the use of SPAD to treat severe liver failure in a
patient with Weil's disease.  
Prikaz bolesnika
Zatajenje jetre, bez obzira na uzrok, sa sobom nosi visoki rizik morbiditeta i
mortaliteta. Brojni toksini koji se nakupljaju tijekom zatajenja jetre slabo su
topljivi u vodi i stoga se transportiraju u cirkulaciju vezani za albumine.
Bubre`na nadomjesna terapija ne utje~e zna~ajnije na koncentraciju bilirubina i
drugih toksina koji se ve`u na albumine u serumu. U bolesnika s jetrenim zata-
jenjem potrebne su dodatne detoksikacijske metode. Postoji nekoliko umjetnih
izvantjelesnih sustava za potporu jetri zasnovanih na albuminskom principu, ali
je njihova dostupnost ograni~ena zbog visokih tro{kova i potrebe za posebnom
edukacijom osoblja koje izvodi postupak. Do sada je opisano nekoliko slu~aje-
va primjene SPAD-a (single pass albumin dialysis) kao u~inkovita alternativa.
Glavna prednost ove metoda je {to se mo`e provesti koriste}i ure|aj za konven-
cionalno nadomje{tanje bubre`ne funkcije. U ovom prikazu, autori opisuju
primjenu SPAD-a za lije~enje te{kog zatajenja jetre u bolesnika s Weilovom
bole{}u. 
Introduction
Severe leptospirosis, also known as Weil's disease, is
characterized by multiorgan involvement, including acute
kidney injury and liver dysfunction. Liver failure, regard-
less of the cause, carries a high risk of morbidity and mor-
tality [1]. Numerous toxins that are accumulated in liver
failure are poorly water-soluble and are transported
through the serum by being bound to albumin. Since it is
impossible to monitor the concentrations of all possible
albumin-bound toxins, the concentration of bilirubin is
used as a surrogate. Although the management of Weil's
disease often includes renal replacement therapy serum
concentration of bilirubin and other albumin-bound toxins
is not significantly altered by hemodyalisis [2]. In order to
eliminate bilirubin and other albumin-bound toxins from
the serum, additional detoxification methods are needed.
There are several artificial extracorporeal liver support
systems based on the principle of albumin, such as
Molecular Adsorbents Recirculating Systems (MARS)
and Fractionated Plasma Separation and Adsorption (FP-
SA), commercialized as Prometheus [3]. Both systems re-
duce hyperbilirubinemia and improve encephalopathy in
patients with liver failure but both are expensive and re-
quire operators with special training. The use of single-
pass albumin dialysis (SPAD) has been shown to be an ef-
fective method of eliminating bilirubin and other albu-
min-bind toxins in several studies in vitro and in vivo [4 –
6]. The main advantage of this method is that it can be per-
formed using conventional renal replacement therapy
(RRT) devices. SPAD dialyzes blood against albumin-
rich dialysate in a single pass through the dialyzer. There
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showed moderate enlargement of liver and spleen. On
October 16th the abdominal CT depicted diffuse intrahep-
atic lesions and a mildly enlarged liver. Due to anuria and
markedly increased levels of urea and creatinine, renal re-
placement therapy was initiated immediately after admis-
sion. The patient was hemodynamically stable. Transeso-
phageal echocardiography showed normal systolic func-
tion with 2nd stage diastolic dysfunction. Despite treat-
ment, the patient gradually developed signs of ence-
phalopathy over the course of the next three days, begin-
ning with confusion and incoherent speech and eventually
reaching stupor. The levels of bilirubin remained above
400 μmol/L with conjugated bilirubin between 80 and 85
percent throughout the first 3 days of hospitalization,
reaching the maximum level of 730.9 μmol/L on the 4th
day, at which point the first cycle of SPAD was initiated.
SPAD was performed in CVVHDF mode using the same
protocol as Seoung Woo Lee et al. Vascular access had
been obtained with a dual lumen hemodialysis catheter via
a femoral vein. Dialysate and replacement solutions were
bicarbonate-buffered. 20 % albumin was mixed into the
dialysate to reach albumin concentration of 2 %. SPAD
was performed in four 4.5-hour sessions over the course of
four days. After 4 sessions of SPAD serum bilirubin was
388.7 mmol/L. Over the course of the next 8 days serum
bilirubin slowly decreased spontaneously, reaching 91.3
μmol/L on the 16th day of treatment. CVVHDF was per-
formed for 18 days. From the 6th to the 11
th
day the patient
required mechanical ventilation due to excessive lung he-
morrhage caused by leptospirosis. Upon admission an-
timicrobial treatment was started with ceftriaxone. Due to
increasing levels of bilirubin and concerns of the possibili-
ty that ceftriaxone could induce cholestasis, the drug was
replaced with ampicillin-sulbactam on the 4th day. The
course of treatment was further complicated by nosocomi-
al sepsis of unknown origin and for that reason antimicro-
bial therapy had to be changed to imipenem and vanco-
mycin on the 8th day. The patient received several erythro-
cyte and platelet transfusions due to normocytic anemia
and severe thrombocytopenia. The patient was extubated
on the 11th day. After discontinuation of sedation there
were no signs of encephalopathy. LP was performed on the
7th day of treatment. Mild pleocytosis with lymphocytic
predominance was noted (6 cells/cmm, 100 % lympho-




This report showed that SPAD was used efficiently to
reduce serum bilirubin, a surrogate marker for albumin-
bound toxins, and thus probably contribute to the resolu-
tion of encephalopathy in a patient with acute liver failure
caused by a severe form of leptospirosis. SPAD was per-
formed using a standard continuous renal replacement
therapy (CRRT) machine, which is used in all ICU settings
have been several reports of using SPAD in patients with
liver disease, including acute and chronic liver failure [6].
In this report, the authors report a case of Weil's disease, in
which SPAD was used to correct severe hyperbilirubine-
mia and improve encephalopathy.
Case report
A 67-year-old man was transferred to the University
Hospital for Infectious Diseases Zagreb from the  County
General Hospital Cakovec, Croatia on October the 14
th
2014. The illness had started 7 days prior to admission.
The patient complained of general weakness, headache,
severe muscle pain in the lower extremities, lumbar pain,
inability to walk, decreased urine output, darker urine, di-
arrhea and vomiting. The patient assumed that he was
afebrile but never measured his body temperature. History
taking revealed that in 2009 he was treated for prostate
adenocarcinoma. Radical prostatectomy and chemothera-
py were performed. Follow-up showed no complications
or recurrence of the original illness. 
The patient lived on a small farm in a village in north-
ern Croatia where he had been regularly exposed to ro-
dents and a variety of domestic animals, including pigs.
He reported occasional moderate alcohol consumption
but denied having consumed mushrooms or any hepato-
toxic drugs.
On admission the physical examination revealed jaun-
dice, severe pain on palpation in all leg muscles and dis-
tended abdomen without hepatomegaly or tenderness in
the right upper quadrant. There were multiple small lacer-
ations on his fingers and palms. Muscle strength in both
lower extremities was decreased. Laboratory examination
was as followed: WBC 16.200 cells/μL, seg 92.7 %, ly
1.8%, Hgb 114 g/L, platelets 141 000 cells/μL, CRP 193.7
mg/L, lactate 1.55 mmol/L, bilirubin 416 μmol/L, conjugat-
ed bilirubin 336 μmol/L, urea 45.2 mmol/L, creatinine 875
μmol/L, Na 136 mmol/L, K 4.0 mmol/L, Cl 96 mmol/L,
Ca 1.71 mmol/L, Mg 0.94 mmol/L, P 1.70 mmol/L, AST
80 U/L, ALT 64 U/L, GGT 189 U/L, ALP 176 U/L, serum
amylase 194 U/L, CK 488 U/L, CK MB 42 U/L, LDH 442
U/L, total protein 43 g/L, albumin 23.4 g/L, INR 0.97, fib-
rinogen 8.2 g/L. Urinalysis showed: protein 3+, leuko-
cytes 2+, erythrocytes  4+. The diagnosis of leptospirosis
was confirmed on the day of admission by microscopic
agglutination test and PCR. Microscopic agglutination
was positive for L. icterohaemorrhagiae (1:1000) and L.
australis (1:500). PCR was positive for leptospirosis.
Two blood culture sets were sterile. Serology tests for
viral hepatitides (C, B, A, E), hemorrhagic fever with re-
nal syndrome (Dobrava, Puumala) and syphilis were neg-
ative. HIV duo test was also negative. 
Chest X-ray showed extensive bilateral infiltrates with
sings of pulmonary congestion. Abdominal ultrasound
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to treat patients with acute kidney failure. With CRRT ma-
chines being widely available and requiring no additional
equipment or specialized personnel training in order to be
used to remove albumin-bound toxins from blood, SPAD
is an efficient and cost-effective potential alternative to
MARS and similar specialized artificial extracorporeal
liver support systems [5, 6]. Several studies have already
demonstrated efficacy of SPAD in patients with acute liv-
er failure (ALF) and acute-on-chronic liver failure
(AoChLF) of various causes [6]. We demonstrated the
first case of SPAD being successfully utilized in a patient
with Weil's disease. 
Despite liver damage and severe hyperbilirubinemia,
the patient's serum concentration of NH3 was normal
throughout the course of treatment. Although ammonia
concentration in venous blood is usually elevated in liver
disease and ammonia does contribute to the genesis of
brain edema, a substantial role of ammonia in causing he-
patic encephalopathy has not been demonstrated in human
clinical studies [7]. In vitro SPAD and CVVHDF induced
a significantly greater reduction of ammonia levels than
MARS [4]. However, in vivo Boonsrirat et al. showed no
significant difference between serum ammonia before and
after treatment with SPAD in patients with liver failure
[6]. 
An issue that deserves further research is that any
method of removing albumin-bound toxins can cause un-
predictable changes in albumin-bound drugs concentra-
tions, which can lead to deleterious effects, especially in
the ICU setting. 
Larger prospective studies comparing SPAD to
MARS and other artificial extracorporeal liver support
systems are still needed. While it has been proven that ar-
tificial extracorporeal liver support systems remove albu-
min-bound toxins, studies are still conflicting regarding
their ability to reduce mortality in patients with liver fail-
ure. It is often cited that without liver transplantation these
systems don't reduce mortality and can be used only as a
bridge therapy. While this is true for patients with irre-
versible liver failure, patients with transient liver dysfunc-
tion may benefit from these systems, as suggested in this
case report and several other aforementioned studies.
In conclusion, despite the observed clinical and labo-
ratory improvement with SPAD, whether this system
could reduce mortality in patients with Weil's disease and
other reversible causes of acute liver failure, remains to be
determined by larger randomized studies. Finally, further
research is necessary to establish the optimal technical
settings for SPAD, including the concentration of human
albumin in dialysate and blood and dialysate flow rates.
Figure 1. Treatment timeline since hospitalization
Slika 1. Vremenska crta lije~enja nakon hospitalizacije
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